Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher
Janux Therapeutics , Inc. (NASDAQ:JANX), a biotech company with a market capitalization of $1.85 billion, saw its Chief Business Officer Meyer Andrew Hollman execute a series of stock transactions, according to a filing with the Securities and Exchange Commission. On March 3, Hollman sold a total of 3,334 shares of Janux Therapeutics common stock, generating proceeds of approximately $107,174. The shares were sold at prices ranging from $31.8848 to $32.8509, near the stock’s 52-week low of $29.63. According to InvestingPro analysis, the stock appears fairly valued at current levels.
The transactions were conducted under a Rule 10b5-1 trading plan that Hollman adopted on September 30, 2024. Following these sales, Hollman retains direct ownership of 82,139 shares in the company.
Additionally, Hollman exercised stock options to acquire 3,334 shares at a price of $4.21 per share, totaling $14,036. This exercise increased his direct holdings to 93,999 shares.
Janux Therapeutics, based in San Diego, California, focuses on the development of cancer immunotherapies and is incorporated in Delaware.
In other recent news, Janux Therapeutics has been the subject of several analyst reports highlighting its ongoing developments and potential in the oncology market. Cantor Fitzgerald’s analyst Josh Schimmer reiterated an Overweight rating with a $200 price target, emphasizing the company’s progress with its ’007 therapy, which is being tested in various patient groups. Schimmer noted that early data for ’007 has shown promising results, with manageable cytokine release syndrome (CRS) and a potential for meaningful progression-free survival benefits. Meanwhile, BTIG analyst Justin Zelin maintained a Buy rating and a $100 price target, focusing on Janux’s competitive positioning in metastatic castration-resistant prostate cancer (mCRPC) with its JANX007 therapy. Zelin highlighted the therapy’s high response rate and durability, as well as the company’s exploration of different dosing regimens.
Clear Street also initiated coverage on Janux Therapeutics with a Buy rating and an $80 price target, expressing optimism about the company’s prospects in the oncology market. The firm highlighted the potential of JANX007 to disrupt the prostate cancer market, which is valued at approximately $5 billion. Clear Street anticipates significant data readouts in 2025, which could enhance Janux’s position in the oncology drug market. These recent developments reflect a strong interest from analysts in Janux Therapeutics’ clinical strategies and product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.